# Anirban Maitra

Source: https://onco.cc/people/anirban-maitra/  
OnCo record `anirban-maitra` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anirban Maitra is a pancreatic cancer pathologist working on catching the disease early and understanding its precursors.

## Summary

Anirban Maitra is Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research at MD Anderson Cancer Center. A pathologist and pancreatic cancer researcher, he leads early-detection efforts including the pancreatic cancer risk and cyst programmes, and studies the biology of pancreatic precursor lesions and KRAS-driven tumorigenesis. His papers include a Gastroenterology review of the opportunities and challenges in early detection of pancreatic cancer and a Modern Pathology analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. His work connects pancreatic ductal adenocarcinoma pathology to multi-cancer early detection and liquid biopsy.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Scientific Director, Sheikh Ahmed Center for Pancreatic Cancer Research, MD Anderson
- Specialisms: Pancreatic cancer; Early detection; Cancer pathology

## Sources

- MD Anderson faculty: https://faculty.mdanderson.org/search?q=Anirban%20Maitra
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Maitra%20A%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Anirban%20Maitra

## Connected records

- cancers: [Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors](https://onco.cc/cancers/ipmn-cystic-precursors/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- key papers: [Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer](https://onco.cc/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/), [Core signaling pathways in human pancreatic cancers revealed by global genomic analyses](https://onco.cc/key-papers/paper-jones-pancreatic-core-pathways-science-2008/), [Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection](https://onco.cc/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/), [Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia](https://onco.cc/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/), [Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers](https://onco.cc/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/), [Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development](https://onco.cc/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/anirban-maitra.json